Saturday, 21 Nov 2026

Empowering Chinese Pharma’s Global Expansion

Contact US
Insight,  China's Pharmaceutical Industry
  • Home
  • About US
  • Policy Hub
  • Categories
    • Drug
    • Company
    • Deals
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Legal / IP
    • Digital
  • Privacy Policy
  • Contact US
My News
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
Insight,  China's Pharmaceutical IndustryInsight,  China's Pharmaceutical Industry
  • Read History
Search
  • Pages
    • Home
    • Blog Index
    • POLICY HUB
    • Contact Us
  • Personalized
    • Read History
  • Categories
    • Company
    • Drug
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Digital
    • Legal / IP
    • Deals
Have an existing account? Sign In
Follow US

CardioACC

  • #
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
  • Rare / orphan disease drugs
  • Auto-immune
  • Vaccine
  • Cell-therapy
  • Multi-specific antibodies
  • CVD
  • AstraZeneca
  • Hengrui Pharmaceuticals
  • SHA: 600276
  • Diabetes
AbbVie and DISCO Pharmaceuticals Strike Strategic Collaboration on AND‑Gated Bispecific Therapeutics – Deal Worth Up to USD 2.5 Billion
CompanyDeals

AbbVie and DISCO Pharmaceuticals Strike Strategic Collaboration on AND‑Gated Bispecific Therapeutics – Deal Worth Up to USD 2.5 Billion

DISCO Pharmaceuticals ("DISCO") announced a strategic collaboration and option‑to‑license agreement with AbbVie (NYSE: ABBV) to discover and develop novel AND‑gated bispecific therapeutics for solid tumors with high unmet medical need.…

November 20, 2026
Sanofi Reportedly Weighs Acquisition of Insmed, Developer of Blockbuster Respiratory Drug Brinsupri

Sanofi Reportedly Weighs Acquisition of Insmed, Developer of Blockbuster Respiratory Drug Brinsupri

November 20, 2026
AbbVie Commits USD 217 Million to Modernize Puerto Rico Biologics Campus with AI‑Integrated Manufacturing

AbbVie Commits USD 217 Million to Modernize Puerto Rico Biologics Campus with AI‑Integrated Manufacturing

November 20, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

CardioACC Initiates Regulatory Study for Groundbreaking 7.5F Intracardiac Ultrasound System

October 21, 2024
Insight,  China's Pharmaceutical Industry

Information You Can Trust: Stay instantly connected with breaking stories and live updates. From politics and technology to entertainment and beyond, we provide real-time coverage you can rely on, making us your dependable source for 24/7 news.

Youtube Medium Rss

About Company

  • Contact Us
  • Advertise with US
  • Complaint
  • Our Team
  • Our Values
  • Privacy Policy
Subscribe Now for Real-time Updates on the Latest Stories!

© 2026 Fineline Information & Technology. Independent intelligence on China’s pharmaceutical industry.  All Rights Reserved.

Fineline Information & Technology
Welcome to Fineline Cube!
Username or Email Address
Password

Lost your password?

Not a member? Sign Up